Carcinoma, Islet Cell [clinicaltrials_resource:02005cf44102c2fa221cb31e2b60c0b8]
condition [clinicaltrials_vocabulary:condition]
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy [clinicaltrials:NCT00003514]Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu [clinicaltrials:NCT00004074]Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors [clinicaltrials:NCT00075439]Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors [clinicaltrials:NCT00084461]Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma [clinicaltrials:NCT00093782]clinicaltrials:NCT00113360clinicaltrials:NCT00131911Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors [clinicaltrials:NCT00227773]clinicaltrials:NCT00363051A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. [clinicaltrials:NCT00428220]clinicaltrials:NCT00428597clinicaltrials:NCT00454363Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00655655]Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer [clinicaltrials:NCT01010126]clinicaltrials:NCT01155258Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma [clinicaltrials:NCT01204476]Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery [clinicaltrials:NCT01229943]clinicaltrials:NCT01465659clinicaltrials:NCT01525082Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors [clinicaltrials:NCT01824875]clinicaltrials:NCT02031536Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery [clinicaltrials:NCT02101918]clinicaltrials:NCT02108782clinicaltrials:NCT02230176clinicaltrials:NCT02259725clinicaltrials:NCT02273752
condition browse [clinicaltrials_vocabulary:condition-browse]
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy [clinicaltrials:NCT00003514]Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu [clinicaltrials:NCT00004074]Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors [clinicaltrials:NCT00075439]Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors [clinicaltrials:NCT00084461]Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma [clinicaltrials:NCT00093782]clinicaltrials:NCT00113360clinicaltrials:NCT00131911Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors [clinicaltrials:NCT00227773]clinicaltrials:NCT00363051A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. [clinicaltrials:NCT00428220]clinicaltrials:NCT00428597clinicaltrials:NCT00454363Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00655655]Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer [clinicaltrials:NCT01010126]clinicaltrials:NCT01155258Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma [clinicaltrials:NCT01204476]Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery [clinicaltrials:NCT01229943]clinicaltrials:NCT01465659clinicaltrials:NCT01525082Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors [clinicaltrials:NCT01824875]clinicaltrials:NCT02031536Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery [clinicaltrials:NCT02101918]clinicaltrials:NCT02108782clinicaltrials:NCT02230176clinicaltrials:NCT02259725clinicaltrials:NCT02273752
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Carcinoma, Islet Cell [clinicaltrials_resource:02005cf44102c2fa221cb31e2b60c0b8]
Bio2RDF identifier
02005cf44102c2fa221cb31e2b60c0b8
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:02005cf44102c2fa221cb31e2b60c0b8
identifier
clinicaltrials_resource:02005cf44102c2fa221cb31e2b60c0b8
title
Carcinoma, Islet Cell
@en
type
label
Carcinoma, Islet Cell [clinicaltrials_resource:02005cf44102c2fa221cb31e2b60c0b8]
@en
Carcinoma, Islet Cell